Market Overview:
The global panheprin market is expected to grow at a CAGR of 5.5% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing incidence of venous thromboembolism (VTE), rising awareness about the benefits of prophylactic use of panheprin, and technological advancements in the field of panheprin therapy. However, factors such as high cost and limited reimbursement for panheprin therapies are restraining the growth of this market. The global panheprin market can be segmented on the basis of type into oral type and injection type. The oral type segment is expected to account for a larger share than the injection type segment in terms revenue during 2018-2030 owing to its ease-of-use and lower cost as compared with injectable forms. On the basis application, this market can be divided into treatment VTE, complications pregnancy, cardioversion atrial fibrillation/flutter etc.
Product Definition:
A heparinoid drug used as an anticoagulant.
Oral Type:
Oral type is the most commonly used form of drug delivery. It's major application includes treatment of diseases like diabetes, arthritis and cancer. The factors that propel its growth include easy availability, low cost and minimal side effects.
The other factor that drives the growth oral drug delivery systems is their non-invasive nature which does not require surgical procedure to administer drugs into body hence it reduces risk associated with surgery and hospital stay thus saving time & cost involved in it.
Injection Type:
Injection type is used in the treatment of asthma, allergies, and other respiratory disorders. It works by decreasing the inflammation of airways which makes it easier to breathe. The drug is available as an oral spray and injection that are prescribed by doctors depending on the severity of a patient’s condition.
Application Insights:
The treatment of venous thromboembolism held the largest revenue share in 2017. Venous thromboembolism (VTE) is a common medical condition that affects mostly hospitalized patients due to immobility. The disease is more prevalent in geriatric population and those who have undergone surgeries recently. According to the Centers for Disease Control and Prevention (CDC), approximately 1 million VTE cases are reported annually in the U.S., resulting in around 60,000 deaths globally.
Regional Analysis:
North America dominated the global market in 2017. High adoption of advanced medical products, increasing healthcare expenditure and favorable reimbursement policies are some of the major factors contributing to its growth. The U.S.
Asia Pacific is expected to register significant growth over the forecast period due to rising disposable income coupled with improving healthcare infrastructure & coverage in emerging countries such as China, India and Thailand. Furthermore, an increase in awareness about blood clotsting disorders among patients will also drive this regional market further on account of Venous Forum’s Vision 2020 initiative that aims at reducing deaths caused by VTE by 20%.
Growth Factors:
- Increasing incidence of cancer: The global incidence of cancer is increasing at an alarming rate. This is expected to drive the demand for Panheprin and other anticancer drugs in the coming years.
- Growing awareness about cancer: There is a growing awareness among people about different types of cancers and their symptoms. This is likely to increase the demand for Panheprin in the near future.
- Rising healthcare expenditure: The global healthcare expenditure is rising rapidly, owing to increasing income levels and technological advancements in the field of medicine. This will create opportunities for Panheprin manufacturers in the coming years.
- Technological advancements: The development of new technologies such as targeted therapy has led to better treatment outcomes for patients with cancer, thereby driving demand for anticancer drugs like Panheprin worldwide . 5) Emerging markets: A large number of people are migrating from rural areas to urban centres in search of better job opportunities and improved living standards, resulting in an increase in health expenditures across emerging markets
Scope Of The Report
Report Attributes
Report Details
Report Title
Panheprin Market Research Report
By Type
Oral Type, Injection Type
By Application
Treatment of Venous Thromboembolism, Complications of Pregnancy, Cardioversion of Atrial Fibrillation/Flutter
By Companies
Shenzhen Hepalink, Bioiberica, Nanjing King-friend, Pfizer, SPL, Dongcheng Biochemicals, Changzhou Qianhong Bio-pharma, Changshan Biochemical, Pharma Action, Baxter, Dongying Tiandong Pharmaceutical, Opocrin, Aspen Oss, Xinbai Pharmaceuticals, Yino Pharma Limited, Sichuan Deebio
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
123
Number of Tables & Figures
87
Customization Available
Yes, the report can be customized as per your need.
Global Panheprin Market Report Segments:
The global Panheprin market is segmented on the basis of:
Types
Oral Type, Injection Type
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Treatment of Venous Thromboembolism, Complications of Pregnancy, Cardioversion of Atrial Fibrillation/Flutter
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Shenzhen Hepalink
- Bioiberica
- Nanjing King-friend
- Pfizer
- SPL
- Dongcheng Biochemicals
- Changzhou Qianhong Bio-pharma
- Changshan Biochemical
- Pharma Action
- Baxter
- Dongying Tiandong Pharmaceutical
- Opocrin
- Aspen Oss
- Xinbai Pharmaceuticals
- Yino Pharma Limited
- Sichuan Deebio
Highlights of The Panheprin Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Oral Type
- Injection Type
- By Application:
- Treatment of Venous Thromboembolism
- Complications of Pregnancy
- Cardioversion of Atrial Fibrillation/Flutter
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Panheprin Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Panheprin is a drug that is used to treat anxiety and depression. It works by affecting the chemicals in the brain that are responsible for these conditions.
Some of the major companies in the panheprin market are Shenzhen Hepalink, Bioiberica, Nanjing King-friend, Pfizer, SPL, Dongcheng Biochemicals, Changzhou Qianhong Bio-pharma, Changshan Biochemical, Pharma Action, Baxter, Dongying Tiandong Pharmaceutical, Opocrin, Aspen Oss, Xinbai Pharmaceuticals, Yino Pharma Limited, Sichuan Deebio.
The panheprin market is expected to register a CAGR of 5.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Panheprin Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Panheprin Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Panheprin Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Panheprin Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Panheprin Market Size & Forecast, 2018-2028
4.5.1 Panheprin Market Size and Y-o-Y Growth
4.5.2 Panheprin Market Absolute $ Opportunity
Chapter 5 Global Panheprin Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Panheprin Market Size Forecast by Type
5.2.1 Oral Type
5.2.2 Injection Type
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Panheprin Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Panheprin Market Size Forecast by Applications
6.2.1 Treatment of Venous Thromboembolism
6.2.2 Complications of Pregnancy
6.2.3 Cardioversion of Atrial Fibrillation/Flutter
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Panheprin Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Panheprin Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Panheprin Analysis and Forecast
9.1 Introduction
9.2 North America Panheprin Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Panheprin Market Size Forecast by Type
9.6.1 Oral Type
9.6.2 Injection Type
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Panheprin Market Size Forecast by Applications
9.10.1 Treatment of Venous Thromboembolism
9.10.2 Complications of Pregnancy
9.10.3 Cardioversion of Atrial Fibrillation/Flutter
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Panheprin Analysis and Forecast
10.1 Introduction
10.2 Europe Panheprin Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Panheprin Market Size Forecast by Type
10.6.1 Oral Type
10.6.2 Injection Type
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Panheprin Market Size Forecast by Applications
10.10.1 Treatment of Venous Thromboembolism
10.10.2 Complications of Pregnancy
10.10.3 Cardioversion of Atrial Fibrillation/Flutter
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Panheprin Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Panheprin Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Panheprin Market Size Forecast by Type
11.6.1 Oral Type
11.6.2 Injection Type
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Panheprin Market Size Forecast by Applications
11.10.1 Treatment of Venous Thromboembolism
11.10.2 Complications of Pregnancy
11.10.3 Cardioversion of Atrial Fibrillation/Flutter
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Panheprin Analysis and Forecast
12.1 Introduction
12.2 Latin America Panheprin Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Panheprin Market Size Forecast by Type
12.6.1 Oral Type
12.6.2 Injection Type
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Panheprin Market Size Forecast by Applications
12.10.1 Treatment of Venous Thromboembolism
12.10.2 Complications of Pregnancy
12.10.3 Cardioversion of Atrial Fibrillation/Flutter
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Panheprin Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Panheprin Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Panheprin Market Size Forecast by Type
13.6.1 Oral Type
13.6.2 Injection Type
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Panheprin Market Size Forecast by Applications
13.10.1 Treatment of Venous Thromboembolism
13.10.2 Complications of Pregnancy
13.10.3 Cardioversion of Atrial Fibrillation/Flutter
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Panheprin Market: Competitive Dashboard
14.2 Global Panheprin Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Shenzhen Hepalink
14.3.2 Bioiberica
14.3.3 Nanjing King-friend
14.3.4 Pfizer
14.3.5 SPL
14.3.6 Dongcheng Biochemicals
14.3.7 Changzhou Qianhong Bio-pharma
14.3.8 Changshan Biochemical
14.3.9 Pharma Action
14.3.10 Baxter
14.3.11 Dongying Tiandong Pharmaceutical
14.3.12 Opocrin
14.3.13 Aspen Oss
14.3.14 Xinbai Pharmaceuticals
14.3.15 Yino Pharma Limited
14.3.16 Sichuan Deebio
